FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977631806> ?p ?o ?g. }

• W2977631806 endingPage "v251" @default.
• W2977631806 startingPage "v251" @default.
• W2977631806 abstract "Abstract Background The immune system plays a pivotal role in modulating response to monoclonal antibodies therapy in cancer. Novel immune-checkpoint inhibitors have demonstrated potent efficacy alone and in combinations with cytotoxic agents in several cancers. In this regard, avelumab in combination with cetuximab might be a relevant re-challenge strategy in RAS wild type (WT) metastatic colorectal cancer (mCRC) patients treated in first line with chemotherapy (CT) in combination with anti-epidermal growth factor receptor (EGFR) drugs and who achieved a complete or partial response. Trial design CAVE Colon is a single arm, multi-center phase II study designed to evaluate the efficacy of avelumab and cetuximab in pre-treated RAS WT mCRC patients. Eligible patients: pathologically confirmed KRAS (exon 2, 3 and 4) and NRAS (exon 2, 3 and 4) WT mCRC treated with a first line CT in combination with an anti-EGFR agent with a major response achieved (complete or partial), who have progressed to a second line therapy, and received no prior immunotherapy. Primary endpoint is overall survival; secondary endpoints are overall response rate according to RECIST 1.1, progression free survival and safety profile. This study seeks to demonstrate a median OS of 11 months by the experimental combination for comparison with historical median OS 8.0 with standard third line treatments, which correspond to an improvement of OS at 6 months from 40% to 57%. With 80% power and 1-sided 5% level test, it was estimated that it would be needed to enrol 66 patients. Considering a potential dropout of approximately 15% of patients, a total of 75 patients will be recruited. The accrual period, started in August 2018, will be 18 months and the total duration of the study will be 36 months. As per April 22nd 2019, thirty-five patients have been enrolled and started the treatment with avelumab 10 mg/kg q14 as a 1-hour i.v. infusion and cetuximab at 400 mg/m2 over 2-hour and subsequently 250 mg/m2 q7 as 1-hour i.v. infusion until disease progression or unacceptable toxicity. Clinical trial identification 2017-004392-32. Legal entity responsible for the study The authors. Funding This study is partially supported by Merck KgA, Darmstadt, Germany. Disclosure E. Martinelli: Advisory / Consultancy: Amgen, Bayer, Merck, Roche, Sanofi, Servier. T. Troiani: Advisory / Consultancy: Amgen, Bayer, Merck, Novartis, Roche. F. Ciardiello: Advisory / Consultancy: Merck Kga, Bayer, Amgen, Rocher, Servier, Pfizer. All other authors have declared no conflicts of interest." @default.
• W2977631806 created "2019-10-10" @default.
• W2977631806 creator A5003014678 @default.
• W2977631806 creator A5006208754 @default.
• W2977631806 creator A5008135397 @default.
• W2977631806 creator A5011531470 @default.
• W2977631806 creator A5012034272 @default.
• W2977631806 creator A5018958639 @default.
• W2977631806 creator A5020655022 @default.
• W2977631806 creator A5038198711 @default.
• W2977631806 creator A5046559582 @default.
• W2977631806 creator A5047539709 @default.
• W2977631806 creator A5050411971 @default.
• W2977631806 creator A5056034569 @default.
• W2977631806 creator A5060428508 @default.
• W2977631806 creator A5079437223 @default.
• W2977631806 creator A5082156303 @default.
• W2977631806 creator A5088094654 @default.
• W2977631806 creator A5088304855 @default.
• W2977631806 creator A5091765229 @default.
• W2977631806 date "2019-10-01" @default.
• W2977631806 modified "2023-10-16" @default.
• W2977631806 title "Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon" @default.
• W2977631806 doi "https://doi.org/10.1093/annonc/mdz246.145" @default.
• W2977631806 hasPublicationYear "2019" @default.
• W2977631806 type Work @default.
• W2977631806 sameAs 2977631806 @default.
• W2977631806 citedByCount "2" @default.
• W2977631806 countsByYear W29776318062021 @default.
• W2977631806 countsByYear W29776318062022 @default.
• W2977631806 crossrefType "journal-article" @default.
• W2977631806 hasAuthorship W2977631806A5003014678 @default.
• W2977631806 hasAuthorship W2977631806A5006208754 @default.
• W2977631806 hasAuthorship W2977631806A5008135397 @default.
• W2977631806 hasAuthorship W2977631806A5011531470 @default.
• W2977631806 hasAuthorship W2977631806A5012034272 @default.
• W2977631806 hasAuthorship W2977631806A5018958639 @default.
• W2977631806 hasAuthorship W2977631806A5020655022 @default.
• W2977631806 hasAuthorship W2977631806A5038198711 @default.
• W2977631806 hasAuthorship W2977631806A5046559582 @default.
• W2977631806 hasAuthorship W2977631806A5047539709 @default.
• W2977631806 hasAuthorship W2977631806A5050411971 @default.
• W2977631806 hasAuthorship W2977631806A5056034569 @default.
• W2977631806 hasAuthorship W2977631806A5060428508 @default.
• W2977631806 hasAuthorship W2977631806A5079437223 @default.
• W2977631806 hasAuthorship W2977631806A5082156303 @default.
• W2977631806 hasAuthorship W2977631806A5088094654 @default.
• W2977631806 hasAuthorship W2977631806A5088304855 @default.
• W2977631806 hasAuthorship W2977631806A5091765229 @default.
• W2977631806 hasBestOaLocation W29776318061 @default.
• W2977631806 hasConcept C121608353 @default.
• W2977631806 hasConcept C126322002 @default.
• W2977631806 hasConcept C143998085 @default.
• W2977631806 hasConcept C2777381376 @default.
• W2977631806 hasConcept C2777701055 @default.
• W2977631806 hasConcept C2779998722 @default.
• W2977631806 hasConcept C2780057760 @default.
• W2977631806 hasConcept C502942594 @default.
• W2977631806 hasConcept C526805850 @default.
• W2977631806 hasConcept C71924100 @default.
• W2977631806 hasConceptScore W2977631806C121608353 @default.
• W2977631806 hasConceptScore W2977631806C126322002 @default.
• W2977631806 hasConceptScore W2977631806C143998085 @default.
• W2977631806 hasConceptScore W2977631806C2777381376 @default.
• W2977631806 hasConceptScore W2977631806C2777701055 @default.
• W2977631806 hasConceptScore W2977631806C2779998722 @default.
• W2977631806 hasConceptScore W2977631806C2780057760 @default.
• W2977631806 hasConceptScore W2977631806C502942594 @default.
• W2977631806 hasConceptScore W2977631806C526805850 @default.
• W2977631806 hasConceptScore W2977631806C71924100 @default.
• W2977631806 hasLocation W29776318061 @default.
• W2977631806 hasOpenAccess W2977631806 @default.
• W2977631806 hasPrimaryLocation W29776318061 @default.
• W2977631806 hasRelatedWork W1908989187 @default.
• W2977631806 hasRelatedWork W2049754458 @default.
• W2977631806 hasRelatedWork W2056426368 @default.
• W2977631806 hasRelatedWork W2280217121 @default.
• W2977631806 hasRelatedWork W2435704186 @default.
• W2977631806 hasRelatedWork W2439403919 @default.
• W2977631806 hasRelatedWork W2898134613 @default.
• W2977631806 hasRelatedWork W3026015583 @default.
• W2977631806 hasRelatedWork W3157508482 @default.
• W2977631806 hasRelatedWork W4292087709 @default.
• W2977631806 hasVolume "30" @default.
• W2977631806 isParatext "false" @default.
• W2977631806 isRetracted "false" @default.
• W2977631806 magId "2977631806" @default.
• W2977631806 workType "article" @default.